Signs positive for biotech deal activity in 2010
This article was originally published in Scrip
Executive Summary
If the activity seen in late December is anything to go by, 2010 could be a bumper year for deal-making, particularly in biotech. December was a busy month, with a raft of new, mostly biotech-related deals involving big pharma. Companies including Teva, AstraZeneca Pfizer, Lilly and GSK announced deals worth over $2 billion in total.